Vima Therapeutics
Clinical trials sponsored by Vima Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Dystonia study seeks to map Disease's Real-World toll Results expected Oct 2026 (estimated)
- New drug combo aims to ease dystonia symptoms Results expected Mar 2027 (estimated)
- Can a Two-Drug combo quiet the tremors Parkinson's patients still feel? Results expected Jun 2027 (estimated)
-
Can a Two-Drug combo quiet the tremors Parkinson's patients still feel?
Disease control Recruiting nowThis phase 2 trial tests an experimental drug called VIM0423 in adults with Parkinson's disease whose tremor does not respond well to standard dopaminergic therapy. Researchers want to see if VIM0423 can reduce tremor severity, improve daily function and quality of life, and be s…
Phase 2 • Sponsor: Vima Therapeutics • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo aims to ease dystonia symptoms
Symptom relief Recruiting nowThis phase 2 trial tests whether VIM0423, a combination of two drugs, can reduce symptoms of isolated dystonia (a movement disorder causing muscle spasms). About 100 adults aged 18-65 with dystonia in at least two body areas will receive either VIM0423 or a placebo. Researchers w…
Phase 2 • Sponsor: Vima Therapeutics • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Dystonia study seeks to map Disease's Real-World toll
Knowledge-focused Recruiting nowThis study watches 200 people with isolated dystonia (affecting more than one body part) to see how the condition changes over time. Researchers will collect information on symptoms, daily activities, pain, and social life using standard rating scales. No experimental treatment i…
Sponsor: Vima Therapeutics • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC